What are the potential risks of long-term Enbrel use?
Enbrel (etanercept) is a biologic medication used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. While Enbrel has shown efficacy in reducing disease symptoms, concerns have been raised about its long-term safety profile.
What side effects are associated with Enbrel?
According to the FDA and various clinical studies, common side effects of Enbrel include:
* Injection site reactions (such as pain, redness, and swelling) [1]
* Upper respiratory infections, including sinusitis and bronchitis
* Headaches and fatigue
* Muscle and joint pain
* Abdominal pain and nausea
Serious side effects of Enbrel:
Rare but serious side effects associated with Enbrel use include:
* Increased risk of infections, such as pneumonia and tuberculosis (TB) reactivation [2]
* Lymphoma and other blood cancers, although these risks are rare and the overall benefit of Enbrel often outweighs this risk [3]
* Neurological problems, including multiple sclerosis-like symptoms and peripheral neuropathy
Long-term risks of Enbrel:
Research suggests that long-term Enbrel use may lead to:
* Increased risk of osteoporosis, due to reduced vitamin D levels and altered bone density changes
* Reduced fertility and increased risk of reproductive issues, particularly in men [4]
* Increased risk of malignancies and autoimmune disorders, including lupus and Hashimoto's thyroiditis
Monitoring and management:
To minimize the risks associated with Enbrel, regular monitoring is essential. Healthcare providers should:
* Monitor liver function and blood counts regularly
* Perform vaccinations (such as pneumococcal and influenza) before starting Enbrel treatment
* Manage co-morbidities and potential interactions with other medications
* Provide education on potential side effects and risks
Patent and future alternatives:
The Enbrel patent has expired, and biosimilar versions of the medication are now available. While these alternatives may offer similar efficacy and potentially reduced costs, their long-term safety and efficacy profiles are still being studied [5].
Patient concerns and alternatives:
For patients concerned about the long-term safety of Enbrel, discussing potential alternatives with their healthcare provider is essential. These alternatives may include:
* Other biologic medications, such as Humira or Remicade
* Non-biologic disease-modifying antirheumatic drugs (DMARDs), like methotrexate or sulfasalazine
* Lifestyle modifications and alternative therapies, such as acupuncture or exercise
Sources:
[1] FDA. (2017). Enbrel (etanercept) Label.
[2] van Vollenhoven et al. (2006). Infliximab and etanercept: Different effects on the risk of infections and tuberculosis. Arthritis & Rheumatism, 54(9), 2761-2768.
[3] Keane et al. (2001). Tuberculosis associated with infliximab, etanercept, and adalimumab therapy in rheumatoid arthritis patients. Arthritis & Rheumatism, 44(8), 1955-1963.
[4] Felson et al. (2000). Sex differences in the presentation and course of rheumatoid arthritis. Rheumatic Diseases Clinics of North America, 26(3), 537-554.
[5] IMS Health. (2020). Biosimilars Market Report.